During 2 years, 6 out of 34 patients presenting with newly diagnosed non-Hodgkin's lymphoma developed central nervous system (CNS) complications. All were male and had diffuse, undifferentiated lymphomas. In all 6 patients, CNS disease developed during, or shortly after, treatment. We suggest that a group at high risk from these complications can be identified and should be considered for a trial of prophylaxis.
Introduction
Involvement of the central nervous system (CNS) in non-Hodgkin's lymphoma (NHL) is now more frequently recognized. In the majority of patients, it is diagnosed when there is advanced disease elsewhere (Young et al., 1979) , but in some it may be the first manifestation of the lymphoma (Littman and Wang, 1975; Venables et al., 1980) . In some patients, CNS disease may develop during or after treatment. Under these circumstances, the CNS acts as a sanctuary site inaccessible to most conventional chemotherapeutic agents.
In 34 consecutive newly diagnosed patients with non-Hodgkin's lymphoma in Nottingham, 6 developed CNS disease. All 6 were male and had diffuse undifferentiated lymphomas. All developed CNS disease during, or shortly after, concluding treatment with a modification of the CHOP regimen described originally by McKelvey et al. (1976) and used by the British National Lymphoma Investigation (BNLI) for the treatment of advanced high grade NHL. None of the cytotoxic drugs employed in this regimen crosses the blood-brain barrier and our experience of CNS relapse in the face of recent or continuing chemotherapy suggests there is a need for a controlled trial of additional treatment as prophylaxis against CNS disease in such high risk patients.
Patients
The patients described were seen at University Hospital, Nottingham during 1980 and 1981. The clinical details are summarized in Tables 1 and 2 . In 5 of the 6 patients, the diagnosis was established on lymph node biopsy, but in Case 5, it was made by histological examination of the testis after orchidectomy for painless swelling. Pathological material in 5 of the patients was examined additionally by the Pathology Panel of the British National Lymphoma Investigation (BNLI) and was classified accordingly (Jelliffe and Vaughan-Hudson, 1981 al., 1976) . Courses were given every 4 to 6 weeks depending on the peripheral blood counts to a minimum of 6 courses and at least 3 courses after complete remission.
In patients 1 and 3, CNS involvement appeared during treatment with CHOP at a time when there appeared to be remission of the disease elsewhere. In patients 2 and 5, CNS disease appeared shortly after the patients completed therapy with CHOP and had achieved clinical remission. In 2 patients (Cases 4 
Discussion
Our own experience in this 2-year period confirms recent suggestions that CNS involvement, particularly lymphomatous leptomeningitis in diffuse nonHodgkin's lymphoma is becoming more common (Littman and Wang, 1975; Young et al., 1979; Bunn et al., 1976; Levitt et al., 1980 (Young et al., 1979) . In 5 of our own cases, lymphomatous infiltration of the bone marrow was seen at presentation. Law et al. (1975) have suggested that lymphoma with retroperitoneal involvement might have predilection for CNS relapse, as was the situation with Case 1. One of our patients (Case 5), had testicular swelling as an initial symptom and Wolley et al. (1976) suggestion that this is 'leukaemia revisited' (Bunn et al., 1976) . Certainly, in the absence of specific CNS prophylaxis in acute lymphoblastic leukaemia, a high proportion of patients develop infiltration of the meninges within 2 years. CNS prophylaxis with cranial irradiation and intra-thecal methotrexate has been clearly shown to improve the prognosis of acute lymphoblastic leukaemia in children (Working Party on Leukaemia in Childhood, 1973; Dritschilo et al., 1976 ) and in adults (Lister et al., 1978b) .
A number of studies have suggested that a related approach ought to be of value in adult NHL. High doses of both methotrexate and cytosine arabinoside given by continuous intravenous infusion can achieve cytotoxic concentrations in the CSF (Tattersail et aL., 1975; Weinstein et al., 1978) . In the case of methotrexate, intravenous infusion has been shown to give a more uniform distribution in the CNS than intra-thecal administration (Shapiro, Young and Mehta, 1975) . High dose methotrexate administered to patients with unfavourable NHL in relapse with CNS disease has produced appreciable improvement (Skarin et aL., 1977) , but at present it is most unlikely that complete erradication can be achieved once overt CNS disease has developed Young et al., 1979; Lister et aL, 1978a) .
The addition of methotrexate to regimes such as BACOP/D (bleomycin, adriamycin, cyclophosphamide, vinicristine and prednisone or dexamethasone) in the initial treatment of patients with diffuse histiocytic or undifferentiated lymphomas has produced encouraging results with only one patient with CNS relapse in a series of 30 patients treated by Canellos, Lister and Skarin (1978) . Also, the use of methotrexate and cytoxine arabinoside may account for the lack of CNS relapses seen with the COMLA (cyclophosphamide, vinicristine, methotrexate with leukovorin rescue and cytarabine) regimen (Sweet et aL, 1980) . Combined cranial irradiation and intrathecal methotrexate has been used after induction of systemic remission in aggressive NHL in adults (Lister et al., 1978a) and has proved effective in children (Murphy and Hustu, 1980 
